Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3326685
Max Phase: Preclinical
Molecular Formula: C22H25FN6O6S
Molecular Weight: 520.54
Molecule Type: Small molecule
Associated Items:
ID: ALA3326685
Max Phase: Preclinical
Molecular Formula: C22H25FN6O6S
Molecular Weight: 520.54
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1nc(S(C)(=O)=O)ccc1Oc1ncnc(OC2CCN(C(=O)c3noc(C(C)C)n3)CC2)c1F
Standard InChI: InChI=1S/C22H25FN6O6S/c1-12(2)19-27-18(28-35-19)22(30)29-9-7-14(8-10-29)33-20-17(23)21(25-11-24-20)34-15-5-6-16(26-13(15)3)36(4,31)32/h5-6,11-12,14H,7-10H2,1-4H3
Standard InChI Key: BXAHBPJBHXQXPU-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 520.54 | Molecular Weight (Monoisotopic): 520.1540 | AlogP: 2.70 | #Rotatable Bonds: 7 |
Polar Surface Area: 150.50 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 0 |
#RO5 Violations: 2 | HBA (Lipinski): 12 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: 0.66 | CX LogP: 2.06 | CX LogD: 2.06 |
Aromatic Rings: 3 | Heavy Atoms: 36 | QED Weighted: 0.45 | Np Likeness Score: -1.37 |
1. Buzard DJ, Kim SH, Lehmann J, Han S, Calderon I, Wong A, Kawasaki A, Narayanan S, Bhat R, Gharbaoui T, Lopez L, Yue D, Whelan K, Al-Shamma H, Unett DJ, Shu HH, Tung SF, Chang S, Chuang CF, Morgan M, Sadeque A, Chu ZL, Leonard JN, Jones RM.. (2014) Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists., 24 (17): [PMID:25088191] [10.1016/j.bmcl.2014.06.071] |
Source(1):